HK1102366A1 - Factor ixa for the treatment of bleeding disorders - Google Patents

Factor ixa for the treatment of bleeding disorders

Info

Publication number
HK1102366A1
HK1102366A1 HK07109313.4A HK07109313A HK1102366A1 HK 1102366 A1 HK1102366 A1 HK 1102366A1 HK 07109313 A HK07109313 A HK 07109313A HK 1102366 A1 HK1102366 A1 HK 1102366A1
Authority
HK
Hong Kong
Prior art keywords
factor ixa
bleeding disorders
treatment
factor
subject
Prior art date
Application number
HK07109313.4A
Other languages
English (en)
Inventor
Shane Donovan
Donald A Baker
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of HK1102366A1 publication Critical patent/HK1102366A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK07109313.4A 2004-03-19 2007-08-27 Factor ixa for the treatment of bleeding disorders HK1102366A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55472604P 2004-03-19 2004-03-19
PCT/US2005/006527 WO2005094873A1 (fr) 2004-03-19 2005-02-28 Facteur ixa pour le traitement de troubles de saignement

Publications (1)

Publication Number Publication Date
HK1102366A1 true HK1102366A1 (en) 2007-11-16

Family

ID=34961495

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07109313.4A HK1102366A1 (en) 2004-03-19 2007-08-27 Factor ixa for the treatment of bleeding disorders

Country Status (10)

Country Link
US (2) US7425539B2 (fr)
EP (1) EP1755652B1 (fr)
JP (2) JP5037331B2 (fr)
AT (1) ATE489105T1 (fr)
AU (1) AU2005228945B2 (fr)
CA (1) CA2557061C (fr)
DE (1) DE602005024955D1 (fr)
ES (1) ES2357132T3 (fr)
HK (1) HK1102366A1 (fr)
WO (1) WO2005094873A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE489105T1 (de) * 2004-03-19 2010-12-15 Baxter Int Faktor ixa zur behandlung von blutungsstörungen
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
WO2013157002A1 (fr) 2012-04-19 2013-10-24 Prolor Biotech Inc. Variants d'oxyntomoduline à action prolongée et procédés pour les produire
CN112661863A (zh) 2012-11-20 2021-04-16 奥普科生物制品有限公司 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
FR3032621A1 (fr) 2015-02-13 2016-08-19 Lab Francais Du Fractionnement Colle biologique et son utilisation comme medicament
KR102057767B1 (ko) * 2015-04-17 2019-12-19 에프. 호프만-라 로슈 아게 응고 인자 및 다중특이적 항체의 조합 요법
EP3988113A1 (fr) 2015-06-19 2022-04-27 OPKO Biologics Ltd. Facteurs de coagulation à action prolongée et ses procédés de production
AU2017205364B2 (en) * 2016-01-07 2021-03-04 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions
BR112019000610A2 (pt) 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
CN107758662B (zh) * 2017-10-10 2019-08-20 中国石油大学(华东) 一种磷酸法活性炭活化时间的确定方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560475A (en) * 1969-06-19 1971-02-02 Baxter Laboratories Inc Prothrombin complex prepared by precipitation with polyethylene glycol
US4357321A (en) * 1980-01-28 1982-11-02 Baxter Travenol Laboratories, Inc. Method and composition for treating clotting factor inhibitors
US4286056A (en) 1980-01-28 1981-08-25 Baxter Travenol Laboratories, Inc. Method for making therapeutic enzyme compositions
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
JP2584443B2 (ja) 1985-04-22 1997-02-26 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 活性化▲ｉ▼▲ｘ▼因子の高収率産生
ES2045167T5 (es) 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
US20040072757A1 (en) 1990-09-04 2004-04-15 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
DE19506633A1 (de) 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
CZ307715B6 (cs) * 1999-02-22 2019-03-06 University Of Connecticut Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu
EP1048736A1 (fr) 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung Construction d'ADN pour l'expression spécifique tissulaire du facteur de coagulation sanguine
US6441144B1 (en) * 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US6624289B1 (en) * 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
EP1244457B1 (fr) * 1999-12-29 2004-10-27 Glaxo Group Limited Utilisation de modulateurs de l'annexine pour le traitement et/ou la prevention de l'arthrite et de maladies arthritiques
US7572619B2 (en) 2000-03-22 2009-08-11 Octagene Gmbh Recombinant blood clotting factors
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US7015193B2 (en) 2001-04-20 2006-03-21 University Of Vermont Compositions and methods to control bleeding
US7977460B2 (en) * 2003-05-19 2011-07-12 National Institute For Biological Standards And Control Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B
ATE489105T1 (de) * 2004-03-19 2010-12-15 Baxter Int Faktor ixa zur behandlung von blutungsstörungen

Also Published As

Publication number Publication date
DE602005024955D1 (de) 2011-01-05
US20050209149A1 (en) 2005-09-22
EP1755652B1 (fr) 2010-11-24
WO2005094873A1 (fr) 2005-10-13
US7767647B2 (en) 2010-08-03
JP2012126743A (ja) 2012-07-05
CA2557061A1 (fr) 2005-10-13
AU2005228945B2 (en) 2010-09-30
JP5037331B2 (ja) 2012-09-26
ES2357132T3 (es) 2011-04-19
US20090069543A1 (en) 2009-03-12
US7425539B2 (en) 2008-09-16
CA2557061C (fr) 2013-08-20
AU2005228945A1 (en) 2005-10-13
EP1755652A1 (fr) 2007-02-28
ATE489105T1 (de) 2010-12-15
JP2007529518A (ja) 2007-10-25

Similar Documents

Publication Publication Date Title
HK1102366A1 (en) Factor ixa for the treatment of bleeding disorders
EA200401525A1 (ru) Способы лечения гепатита (варианты )
RS91004A (en) Methods of treating ileus
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
TWI319708B (en) Methods and compositions for altering cell fuction
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
WO2006042249A3 (fr) Methodes et compositions de traitement de la douleur de migraine
TW200612892A (en) Novel compounds
WO2004069190A3 (fr) Therapie combinee destinee au traitement de troubles associes a une carence proteique
TW200510416A (en) P38 inhibitors and methods of use thereof
GB2442915B (en) Perylenequinone derivatives and uses thereof
TW200505416A (en) Bi-aryl compound having immunosuppressive activity
TW200700071A (en) Novel use
WO2004110380A3 (fr) Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
UA85676C2 (en) Carbonyl compounds
WO2004007676A3 (fr) Therapie combinee servant a traiter des tumeurs
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
TW200635920A (en) Pyrazinedicarboxamides and their use
MXPA05005915A (es) Soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas.
BR0308753A (pt) Método para produzir pseudo-ilhotas

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140228